• SSY Group won China NMPA registration for its gadobutrol bulk drug, clearing it for use in marketed contrast-agent preparations.
• Gadobutrol is a macrocyclic MRI contrast agent used in adults and children, including full-term newborns.
• The group flagged development of an integrated gadolinium franchise spanning bulk drugs and injection products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260721-12250432), on July 20, 2026, and is solely responsible for the information contained therein.